Ghrelin and synthetic growth hormone secretagogues are cardioactive molecules with identities and differences

Seminars in Vascular Medicine

Volumn 4, Issue 2, 2004, Pages 107-114

  Benso, Andrea ^a,b   Broglio, Fabio ^a,b   Marafetti, Lisa ^a,b   Lucatello, Barbara ^a,b   Seardo, Maria Angela ^a,b   Granata, Riccarda ^a,b   Martina, Valentino ^a,b   Papotti, Mauro ^a,b   Muccioli, Giampiero ^a,b   Ghigo, Ezio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Cardiovascular system; GH Secretagogues; Ghrelin; GHS receptors; Heart; Hexarelin

Indexed keywords

APOLIPOPROTEIN E; CAPROMORELIN; CD36 ANTIGEN; DOXORUBICIN; GHRELIN; GROWTH HORMONE RELEASING PEPTIDE 1; GROWTH HORMONE SECRETAGOGUE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; HEXARELIN; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; IBUTAMOREN; PRALMORELIN; RECEPTOR SUBTYPE; TYROSYLALANYLHEXARELIN; UNCLASSIFIED DRUG;

ACYLATION; ANTIGEN EXPRESSION; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CELL PROTECTION; COMPARATIVE STUDY; DISEASE COURSE; ENDOTHELIUM CELL; GROWTH HORMONE RELEASE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART PROTECTION; HORMONE ACTION; HORMONE BINDING; HUMAN; NEUROENDOCRINOLOGY; NONHUMAN; REPERFUSION INJURY; REVIEW; STOMACH; TISSUE DISTRIBUTION;

ANIMALS; BINDING SITES; CARDIOVASCULAR PHYSIOLOGY; ENDOTHELIUM, VASCULAR; HUMANS; MUSCLE CONTRACTION; PAPILLARY MUSCLES; RECEPTORS, G-PROTEIN-COUPLED; REGIONAL BLOOD FLOW; VASODILATION; VENTRICULAR FUNCTION, LEFT;

EID: 7244251619     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-835367     Document Type: Review

References (63)

1. Smith RG, Van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997;18:621-645
2. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-660
3. Kojima M, Hosoda H, Matsuo H, Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 2001;12:118-122
4. Smith RG, Leonard R, Bailey AR, et al. Growth hormone secretagogue receptor family members and ligands. Endocrine 2001;14:9-14
5. Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol 2002;440:235-254
6. Horvath TL, Diano S, Sotonyi P, Heiman M, Tschop M. Minireview: ghrelin and the regulation of energy balance - a hypothalamic perspective. Endocrinology 2001;142:4163-4169
7. Muccioli G, Papotti M, Locatelli V, Ghigo E, Deghenghi R. Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrinol Invest 2001;24:RC7-RC9
8. Smith RG, Griffin PR, Xu Y, et al. Adenosine: a partial agonist of the growth hormone secretagogue receptor. Biochem Biophys Res Commun 2000;276:1306-1313
9. Tullin S, Hansen BS, Ankersen M, Moller J, Von Cappelen KA, Thim L. Adenosine is an agonist of the growth hormone secretagogue receptor. Endocrinology 2000;141:3397-3402
10. Deghenghi R, Broglio F, Papotti M, Muccioli G, Ghigo E. Targeting the ghrelin receptor: orally active GHS and cortistatin analogs. Endocrine 2003;22:13-18
11. Deghenghi R, Papotti M, Ghigo E, Muccioli G. Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J Endocrinol Invest 2001;24:RC1-RC3
12. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000;85:4908-4911
13. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001;86:4753-4758
14. Ravussin E, Tschop M, Morales S, Bouchard C, Heiman ML. Plasma ghrelin concentration and energy balance: overfeeding and negative energy balance studies in twins. J Clin Endocrinol Metab 2001;86:4547-4551
15. Tschop M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001;24:RC19-RC21
16. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002;87:240-244
17. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001;104:2034-2038
18. Broglio F, Gottero C, Benso A, et al. Ghrelin and the endocrine pancreas. Endocrine 2003;22:19-24
19. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714-1719
20. Broglio F, Arvat E, Gottero C, et al. Natural and synthetic growth hormone secretagogue. Do they have therapeutical potential? Treat Endocrinol 2003;2:153-163
21. Muccioli G, Broglio F, Tarabra E, Ghigo E. Known and unknown growth hormone secretagogue receptors and their ligands. In: Ghigo E, ed. Ghrelin (More than Simply a Natural GH Secretagogue and/or an Orexigenic Factor). Boston: Kluwer Academic; 2004:27-48
22. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002;159:1029-1037
23. Bedendi I, Alloatti G, Marcantoni A, et al. Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharrnacol 2003;476:87-95
24. Ong H, Bodart V, McNicoll N, Lamontagne D, Bouchard JF. Binding sites for growth hormone-releasing peptide. Growth Horm IGF Res 1998;8(suppl. B):137-140
25. Bodart V, Bouchard JF, McNicoll N, et al. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res 1999;85:796-802
26. Muccioli G, Broglio F, Valetto MR, et al. Growth hormone-releasing peptides and the cardiovascular system. Ann Endocrinol (Paris) 2000;61:27-31
27. Papotti M, Ghe C, Cassoni P, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 2000;85:3803-3807
28. Katugampola SD, Pallikaros Z, Davenport AP. [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with atherosclerosis. Br J Pharrnacol 2001;134:143-149
29. Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 2002;90:844-849
30. De Gennaro Colonna V, Rossoni G, Bernareggi M, Muller EE, Berti F. Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency. Cardiologia 1997;42:1165-1172
31. De Gennaro Colonna V, Rossoni G, Bernareggi M, Muller EE, Berti F. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin. Eur J Pharmacol 1997;334:201-207
32. Rossoni G, De Gennaro Colonna V, Bernareggi M, Polvani GL, Muller EE, Berti F. Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. J Cardiovasc Pharrnacol 1998;32:260-265
33. Locatelli V, Rossoni G, Schweiger F, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 1999;140:4024-4031
34. MacAndrew JT, Ellery SS, Parry MA, Pan LC, Black SC. Efficacy of a growth hormone-releasing peptide mimetic in cardiac ischemia/reperfusion injury. Eur J Pharmacol 2001;432:195-202
35. Shen YT, Lynch JJ, Hargreaves RJ, Gould RJ. A growth hormone secretagogue prevents ischemic-induced mortality independently of the growth hormone pathway in dogs with chronic dilated cardiomyopathy. J Pharmacol Exp Ther 2003;306:815-820
36. Weckers F, Van Herck E, Isgaard J, Van den Berghe G. Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model. Endocrinology 2000;141:3993-3999
37. Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R. Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Basic Res Cardiol 2003;98:401-405
38. Chang L, Ren Y, Liu X, et al. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol 2004;43:165-170
39. Torsello A, Bresciani E, Rossoni G, et al. Ghrelin plays a minor role in the physiological control of cardiac function in the rat. Endocrinology 2003;144:1787-1792
40. th Annual Meeting of the Endocrine Society. Philadelphia, Pa: 2003:P2-223
41. Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001;104:1430-1435
42. Shimizu Y, Nagaya N, Teranishi Y, et al. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun 2003;310:830-835
43. Tivesten A, Bollano E, Caidahl K, et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology 2000;141:60-66
44. King MK, Gay DM, Pan LC, et al. Treatment with a growth hormone secretagogue in a model of developing heart failure: effects on ventricular and myocyte function. Circulation 2001;103:308-313
45. Xu XB, Cao JM, Pang JJ, et al. The positive inotropic and calcium-mobilizing effects of growth hormone-releasing peptides on rat heart. Endocrinology 2003;144:5050-5057
46. Bedendi I, Gallo MP, Malan D, Levi RC, Alloatti G. Role of endothelial cells in modulation of contractility induced by hexarelin in rat ventricle. Life Sci 2001;69:2189-2201
47. Filigheddu N, Fubini A, Baldanzi G, et al. Hexarelin protects H9c2 cardiomyocytes from doxorubicin-induced cell death. Endocrine 2001;14:113-119
48. Pang JJ, Xu RK, Xu XB, et al. Hexarelin protects rat cardiomyocytes from angiotensin II-induced apoptosis in vitro. Am J Physiol Heart Circ Physiol 2004;286:H1063-H1069
49. Broglio F, Benso A, Gottero C, et al. Non-acylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans. J Endocrinol Invest 2003;26:192-196
50. Bisi G, Podio V, Valetto MR, et al. Acute cardiovascular, and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest 1999;22:266-272
51. Bisi G, Podio V, Valetto MR, et al. Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol 1999;381:31-38
52. Broglio F, Benso A, Valetto MR, et al. Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy. Endocrine 2001;14:105-108
53. Imazio M, Bobbio M, Broglio F, et al. GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy. Eur J Heart Fail 2002;4:185-191
54. Broglio F, Guarracino F, Benso A, et al. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. Eur J Pharmacol 2002;448:193-200
55. Nagaya N, Kojima M, Uematsu M, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001;280:R1483-R1487
56. Nagaya N, Miyatake K, Uematsu M, et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 2001;86:5854-5859
57. Enomoto M, Nagaya N, Uematsu M, et al. Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin Sci 2003;105:431-435
58. Matsumura K, Tsuchihashi T, Fujii K, Abe I, Iida M. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 2002;40:694-699
59. Matsumura K, Tsuchihashi T, Fujii K, Iida M. Neural regulation of blood pressure by leptin and the related peptides. Regul Pept 2003;114:79-86
60. Wiley KE, Davenport AP. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002;136:1146-1152
61. Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003;52:2546-2553
62. Tritos NA, Kissinger KV, Manning WJ, Danias PG. Association between ghrelin and cardiovascular indexes in healthy obese and lean men. Clin Endocrinol 2004;60:60-66
63. Pemberton C, Wimalasena P, Yandle T, Soule S, Richards M. C-terminal pro-ghrelin peptides are present in the human circulation. Biochem Biophys Res Commun 2003;310:567-573